• What is EQ-5D?
• EQ-5D products
• How to obtain EQ-5D
• Valuation of EQ-5D
  • Value sets
  • References
• Population norms
• Proceedings search
• Reference search
• EQ-5D publications
• FAQs

Badia X, Roset M, Monserrat S, Herdman M. The Spanish VAS tariff based on valuation of EQ-5D health states from the general population. In: Rabin RE et al, editors. EuroQol Plenary meeting Rotterdam 1997, 2-3 October. Discussion papers. Centre for Health Policy & Law, Erasmus University, Rotterdam, 1998: 93-114.

Badia X, Roset R, Herdman, M, Kind P. A comparison of GB and Spanish general population time trade-off values for EQ-5D health states. Med Decis Making 2001; 21(1): 7-16.

Brazier J, Deverill M, Green C, Harper R, Booth A. A review of the use of health status measures in economic evaluation. NHS R&D HTA programme, Health Technol Assess 1999; 3(9):i-164.

Brazier J, Akehurst R, Brennan A, Dolan P, Klaxton C, McCabe C, O’Hagan T, Sculpher M, Tsuchiya A. Should patients have a greater role in valuing health states: whose well-being is it anyway? Paper presented at the CES/HESG conference, Paris, January 2004.

Bridges J. Stated preference methods in health care evaluation: an emerging methodological paradigm in health economics. Appl Health Econ Health Policy 2003; 2(4):213-224.

Brooks R, Rabin R, de Charro F, editors. The measurement and valuation of health status using EQ-5D: a European perspective. Kluwer Academic Publishers 2003.

Chilcott J, McCabe C, Tappenden P, O'Hagan A, Cooper N, Abrams K, Claxton K. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. BMJ 2003; 326(7388):522; discussion 522.

Claes C, Greiner W, Uber A, Graf von der Schulenburg JM. An interview-based comparison of the TTO and VAS values given to EuroQol states of health by the general German population. In: Greiner W, J-M. Graf v.d. Schulenburg, Piercy J, editors. EuroQol Plenary Meeting, 1-2 October 1998. Discussion papers. Centre for Health Economics and Health Systems Research, University of Hannover, Germany. Uni-Verlag Witte, 1999; 13-39.

Cleemput I. Economic evaluation in renal transplantation: outcome assessment and cost-utility of non-compliance. Acco, Leuven 2003.

Culyer AJ. The normative economics of health care finance and provision. In: McGuire A, Fenn P, Mayhew K, editors. Providing health care. Oxford University Press, 1991.

Derrett S, Devlin N, Hansen P, Herbison P. Prioritising patients for elective surgery. A prospective study of clinical priority assessment criteria in New Zealand. Int J Technol Assess Health Care 2003; 19(1):91-105.

Devlin NJ, Hansen P, Kind P, Williams A. Logical inconsistencies in survey respondents' health state valuations - a methodological challenge for estimating social tariffs. Health Econ 2003; 12(7):529-544.

Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35(11):1095-1108.

Dolan P. Whose preferences count? Med Decis Making 1999; 19(4):482-486.

Dolan P, Stalmeier P. The validity of time trade-off values in calculating QALYs: constant proportional time trade-off versus the proportional heuristic. J Health Econ 2003; 22(3):445-458.

Drummond MF, Sculpher M, Torrance G, O'Brien B, Stoddart G. Methods for the economic evaluation of health care programmes. Oxford University Press, 3rd edition 2005.

Greiner W, Weijnen T, Nieuwenhuizen M, et al. A single European currency for EQ-5D health states. Results from a six country study. Eur J Health Econ 2003; 4(3):222-231.

Greiner W, Claes C, Buschbach JJV, Graf von der Schulenburg JM. Validating the EQ-5D with time trade off for the German population. Eur J Health Econ 2005; 6(2):124-130.

Hicks JR. The four consumer's surpluses. Rev Econ Stud 1943; 11(1):31-41.

Jelsma J, Hansen K, De Weerdt W, De Cock P, Kind P. How do Zimbabweans value health states? Popul Health Metr 2003; 1(1):11.

Kind P. Guidelines for value sets in economic and non-economic studies using EQ-5D. Chapter 4 in: Brooks R, Rabin R, de Charro F, editors. The measurement and valuation of health status using EQ-5D: a European perspective. Kluwer 2003.

Kind P, Hardman G, Macran S. UK Population norms for EQ-5D. York Centre for Health Economics, Discussion Paper, University of York 1999.

Lamers LM, McDonnell J, Stalmeier PFM, Krabbe PFM, Busschbach JJV. The Dutch Tariff: Results and arguments for an effective design for national EQ-5D valuation studies. Accepted for publication in Health Economics.

MVH Group. The Measurement and Valuation of Health. Final report on the modelling of valuation tariffs. York Centre for Health Economics, 1995.

Naylor CD, Llewellyn-Thomas HA. Utilities and preferences for health states: time for a pragmatic approach? J Health Serv Res Policy 1998; 3(3):129-131.

National Institute of Clinical Excellence. Guidance for Manufacturers and Sponsors. Technology Appraisal Process Series No.5, 2001 (http://www.nice.org.uk).

National Institute for Clinical Excellence. Guide to methods of technology appraisal 2004 (http://www.nice.org.uk/pdf/TAP_Methods.pdf).

Ohinmaa A, Eija H, Sintonen H. Modelling EuroQol values of Finnish adult population. In: Badia X, Herdman M, Segura A, editors. EuroQol Plenary Meeting Barcelona 1995. Discussion Papers. Institut Universitari de Salut Publica de Catalunya, 1996; 67-76.

Ohinmaa A, Sintonen H. Inconsistencies and modelling of the Finnish EuroQol (EQ-5D) preference values. In: Greiner W, J-M. Graf v.d. Schulenburg, Piercy J, editors. EuroQol Plenary Meeting, 1-2 October 1998. Discussion papers. Centre for Health Economics and Health Systems Research, University of Hannover, Germany. Uni-Verlag Witte, 1999; 57-74.

Parkin D, McNamee P, Jacoby A, Miller P, Thomas S, Bates D. A cost-utility analysis of interferon beta for multiple sclerosis. Health Technol Assess 1998; 2(4): i-58.

Parkin D, Devlin N. Is there a case for using visual analogue scale valuations in cost- utility analysis? Health Econ 2006 [in press].

Prevolnik Rupel V, Rebolj M. The Slovenian VAS Tariff based on valuations of EQ-5D health states from the general population. In: Cabasés JM, Gaminde I, editors. Proceedings of the 17th Plenary Meeting of the EuroQol Group. Universidad Pública de Navarra 2001; 23-47.

Richardson J. Cost Utility Analysis: what should be measured? Soc Sci Med 1994; 39(1):7-21.

Robinson A, Parkin D. Recognising diversity in public preferences: the use of preference sub-groups in cost-effectiveness analysis. A response to Sculpher and Gafni. Health Econ 2002; 11(7):649.

Sculpher M, Gafni A. Recognising diversity in public preferences: the use of preference sub-groups in cost-effectiveness analysis. Health Econ 2001; 10(4):317-324.

Sculpher M, Gafni A. Recognising diversity in public preferences: the use of preference sub-groups in cost-effectiveness analysis. Authors Reply. Health Econ 2002; 11(7):653.

Sen A. Social choice theory: a re-examination. Econometrica 1977; 45(1):53-90.

Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005; 43(3):203-220.

Sutherland HJ, Llewellyn-Thomas H, Boyd NF, Till JE. Attitudes toward quality of survival. The concept of "maximal endurable time". Med Decis Making 1982; 2(3):299-309.

Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ 1986; 5(1):1-30.

Tsuchiya A, Ikeda S, Ikegami N, et al. Estimating an EQ-5D population value set: The case of Japan. Health Econ 2002; 11(4):341-353.

Weinstein, MC, Siegel J, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost effectiveness in health and medicine. JAMA 1996; 276(15):1253-1258.

Wittrup-Jensen KU, Lauridsen JT, Gudex C, Brooks R, Pedersen KM. Estimating Danish EQ-5D tariffs using TTO and VAS. In: Norinder A, Pedersen K, Roos P, editors. Proceedings of the 18th Plenary Meeting of the EuroQol Group. IHE, The Swedish Institute for Health Economics 2002; 257-292.